Manufacturing

Hitachi Chemical to acquire apceth Biopharma

apceth Biopharma, a contract manufacturing organization in the field of cell and gene therapy, announced that Hitachi Chemical Co., Ltd. will enter into an agreement to acquire all shares of apceth Biopharma.

NextPharma to acquire Santen’s Tampere manufacturing facility

NextPharma, a European pharmaceutical contract development and manufacturing organization (CDMO), has agreed to acquire Santen’s Tampere manufacturing facility and associated operations.

BioNTech to acquire MAB Discovery’s antibody generation unit

BioNTech, a biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.

Takeda completes $62bn acquisition of Irish biotech firm Shire

Japan-based Takeda Pharmaceutical has completed its previously announced $62bn acquisition of Irish rare disease biotech company Shire.

Lilly to acquire Loxo Oncology for $8bn

Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.

Catalent to invest $200m in biologics business

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.

Bristol-Myers Squibb to acquire Celgene for $74bn

Pharma giant Bristol-Myers Squibb has agreed to acquire US biotechnology company Celgene in a cash-cum-stock deal worth around $74bn.

Portola secures FDA approval for Andexxa generation 2 manufacturing process

The US Food and Drug Administration (FDA) has approved Portola Pharmaceuticals’ Prior Approval Supplement (PAS) for the manufacturing process of second generation Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo].

Pfizer, GSK to create $13bn consumer healthcare joint venture

Pfizer and the UK-based GlaxoSmithKline (GSK) have agreed to merge their respective consumer healthcare businesses into a new joint venture (JV), which will be majority owned by the latter.